Mammoth与Regeneron合作 - Mammoth与Regeneron宣布合作研究、开发和商业化体内CRISPR基因编辑疗法[1] - Mammoth将获得总额为1亿美元的前期付款和股权投资[1] - Regeneron正在开发利用抗体靶向的腺相关病毒载体(AAVs)来增强基因药物有效传递到特定组织和细胞类型[1] Mammoth的技术优势 - Mammoth正在开发新型超紧凑核酸酶和相关基因编辑系统，具有比其他CRISPR系统更小的尺寸[1] - Mammoth的超紧凑CRISPR系统解决了病毒传递的尺寸限制，并与Regeneron的靶向AAV技术相辅相成[2] - Mammoth的基因编辑系统和Regeneron的传递技术有望克服重大的传递障碍，有效到达全身各种组织，影响多种疾病[2] 商业化和发展 - Mammoth的编辑技术将获得广泛使用，Regeneron将领导开发和商业化[4]

Oral presentations include updated results from clinical study of otoferlin gene therapy DB-OTO demonstrating restoration in children with profound genetic hearing loss Additional presentations cover progress in novel genetic medicine delivery systems and immune response modulation TARRYTOWN, N.Y., April 22, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that new and updated data across its genetic medicines portfolio will be presented at the American Society of Gene ...

NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ:REGN). The investigation concerns whether Regeneron and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [Click here to learn more about the investigation] On April 10, 2024, the U.S. Department of Justice ("DOJ") issued a press release announci ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Regeneron (REGN) , which belongs to the Zacks Medical - Biomedical and Genetics industry.This biopharmaceutical company has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 10.51%.For the most recent quarter, Regeneron was expected to p ...

Shares of Regeneron Pharmaceuticals (REGN) were down 1.70% on Apr 11, following a complaint filed by the U.S. Department of Justice against the company, alleging fraudulent drug pricing practices related to its lead drug, Eylea.The Department filed a complaint under the False Claims Act (FCA) against Regeneron, which manufactures and sells the ophthalmology drug, Eylea. The lawsuit was originally filed under the qui tam or whistleblower provisions of the FCA.Eylea is an anti-vascular endothelial growth fact ...

Key TakeawaysRegeneron shares were lower ahead of the opening bell Thursday morning after the DOJ filed a complaint accusing the drugmaker of manipulating Medicare’s drug pricing process.The DOJ Alleges the company failed to report credit card fees that it paid distributors.Regeneron shares may find support around $915 from a nine-month trendline. A breakdown below this level could see a retest of a key horizontal line near $835. Shares in biotech giant Regeneron Pharmaceuticals (REGN) go under the microsco ...

About this content About Josh Lamb After graduating from the University of Kent in the summer of 2022 with a degree in History, Josh joined Proactive later that year as a journalist in the UK editorial team. Josh has reported on a range of areas whilst at Proactive, including energy companies during a time of global crisis, aviation and airlines as the sector recovers from the pandemic, as well as covering economic, social and governance issues. Read more About the publisher Proactive financial news and ...

Linvoseltamab关键试验数据 - Regeneron Pharmaceuticals, Inc.宣布了linvoseltamab在复发/难治性多发性骨髓瘤（MM）患者中的关键试验数据[1] - Linvoseltamab是一种正在研究的双特异性抗体，旨在连接多发性骨髓瘤细胞上的B细胞成熟抗原（BCMA）和表达CD3的T细胞，以促进T细胞激活和杀伤癌细胞[2] - Linvoseltamab治疗导致早期、持久且随时间加深的反应，对于这些经过重度治疗的患者群体来说，这些都是关键的疗效指标[3] - Linvoseltamab数据显示，117名患者中71%的客观反应率（ORR），46%的患者达到完全缓解（CR）或更好，62%的患者达到非常好的部分缓解（VGPR）或更好[4]

NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms. If you own REGN please contact Justin Kuehn, Esq. by email at justin@kuehn.law or call (833) 672-0814.  The consultation and case are fr ...

业绩总结 - EYLEA在去年第四季度的净销售额达到1.23亿美元，EYLEA系列在整个市场中占据了约49%的份额[5] - 非GAAP毛利率指导在89%至91%之间，2024年的启动成本会影响毛利率[27] - 公司在投资这些项目时会进行严格的流程，根据多种因素来平衡资本投资[32] 用户数据 - 近期已经发货超过10万份EYLEA HD订单，这对于医生来说是一个重要的里程碑，有助于提高对产品安全性的信心[6] - 大部分转换来自EYLEA 2毫克到HD，但也有来自其他品牌药物和Avastin的转换，以及逐渐增长的新患者[7] - 96周数据支持了EYLEA HD的临床特性，实际处方经验也非常积极[15] 未来展望 - COPD市场潜力巨大，美国有约30万名2型COPD患者，而G7国家总共约55万名患者，这为Dupixent的推出提供了强大机会[18] - Dupixent有望成为COPD领域的首个获批生物制剂，市场上对于这一产品的期待很高[19] - linvoseltamab具有出色的特点，如果与竞争对手以相同的价格和准入条件同时推出，将完全占据市场[35] 新产品和新技术研发 - Regeneron计划在肥胖领域进行研究，希望通过肌肉保护抗体来改善健康结果[41] - Regeneron将进行第二阶段研究，结合semaglutide和肌肉保护抗体，评估体重和脂肪减少情况[44] - Regeneron还有其他肥胖项目，包括leptin受体激动剂抗体和GPR75基因的研究[50] 市场扩张和并购 - 公司已经开始加快偿还与Sanofi的合作中的发展余额，截至2023年底，余额为23亿美元[30] - Regeneron不会盲目进行并购，会根据内部情况选择性地进行交易[54] - 未来可能考虑分红，特别是在发展平衡得到解决后[55]